All In Biotech

Drug Trial Radar · NCT05938946

Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults

A Phase I, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of L608 for Inhalation in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Aug 30, 2023

Primary completion

Sep 2, 2024

Study completion Sep 2, 2024

Sponsor

Lead sponsor
Pharmosa Biopharm Inc.Industry
Sponsor type
Industry
Collaborators
Novotech (Australia) Pty Limited
First posted
Jul 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I, randomized, double-blinded, placebo-controlled single ascending dose, sequential-group study to evaluate the safety, tolerability, and PK of single ascending doses of L608 inhalation in healthy volunteers.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • L608 Inhalation SolutionDrug

    subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo

  • Placebo solutionDrug

    subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of dose limiting toxicity (DLT)Time frame: Baseline to Day 14
  2. The incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Baseline to Day 21
  3. Frequency and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Baseline to Day 21

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research Pty Ltd

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.